← Annexon, Inc. (ANNX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Annexon, Inc. (ANNX)
Pharmaceutical Preparations · market cap $583M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Annexon, Inc. (ANNX) is a clinical-stage pharmaceutical company with a market cap of ~$224M and ~99 employees, running three Phase 3 programs simultaneously: vonaprument in Geographic Atrophy (GA), tanruprubart in Guillain-Barré Syndrome (GBS), and ANX005 in warm autoimmune hemolytic anemia (wAIHA). The company holds $175.2M in cash but burns aggressively (~$185M R&D in fiscal 2025), leaving only ~11 months of runway ahead of two binary Phase 3 readouts expected in Q4 2026.
The catalyst path
- 2026-10-31 (est.)Phase 3 · Vonaprumentimp 9/10
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 3 · Tanruprubartimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Vonaprument | Phase 3 | Geographic Atrophy |
| ANX007 | Phase 2 | Geographic Atrophy |
| Tanruprubart | Phase 3 | Guillain-Barre Syndrome |
| ANX005 | Phase 3 | Warm Autoimmune Hemolytic Anemia (wAIHA) |
Price & technical context
3-month
-29.5%
6-month
-23.6%
12-month
+38.6%
52-wk range
$2.68–$6.96
vs 50-day MA
-11.7%
vs 200-day MA
-21.6%
Realized vol
72.3%
Max drawdown
-81.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ANNX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.